AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The Company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers. 
Type
Public
HQ
Redwood City, US
Founded
2005
Size (employees)
39 (est)
Website
acelrx.com
AcelRx Pharmaceuticals was founded in 2005 and is headquartered in Redwood City, US
Report incorrect company information

AcelRx Pharmaceuticals Office Locations

AcelRx Pharmaceuticals has an office in Redwood City
Redwood City, US (HQ)
351 Galveston Dr
Show all (1)
Report incorrect company information

AcelRx Pharmaceuticals Financials and Metrics

AcelRx Pharmaceuticals Financials

AcelRx Pharmaceuticals's revenue was reported to be $8 m in FY, 2017
USD

Revenue (Q1, 2018)

343 k

Gross profit (Q1, 2018)

(771 k)

Gross profit margin (Q1, 2018), %

(224.8%)

Net income (Q1, 2018)

(11.6 m)

EBIT (Q1, 2018)

(8.3 m)

Market capitalization (25-May-2018)

164.2 m

Closing share price (25-May-2018)

3.2

Cash (31-Mar-2018)

43.6 m

EV

130.1 m
AcelRx Pharmaceuticals's current market capitalization is $164.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

29.5 m5.2 m19.3 m17.4 m8 m

Revenue growth, %

(82%)269%(10%)

Cost of goods sold

1.8 m12.3 m10.7 m

Gross profit

17.5 m5 m(2.7 m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

15.4 m3 m4.5 m3.4 m3.1 m2.7 m343 k

Cost of goods sold

3.6 m3 m2.6 m4.1 m3.5 m1.1 m

Gross profit

(574 k)1.6 m787 k(1 m)(884 k)(771 k)

Gross profit Margin, %

(19%)34%23%(33%)(33%)(225%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

88.4 m60 m107.9 m80.3 m52.9 m

Accounts Receivable

3.3 m5.8 m1.5 m

Inventories

897 k948 k466 k2.2 m956 k

Current Assets

104.6 m76.3 m118.9 m89.1 m63.4 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

95 m105.4 m97.8 m92.5 m72.3 m62.1 m43.6 m

Accounts Receivable

17.4 m3.2 m4.2 m2 m2.7 m2.1 m772 k

Inventories

910 k1.3 m1.4 m1.9 m1.6 m666 k

Current Assets

122.6 m112.8 m105.6 m96.9 m78 m66.8 m53.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(23.4 m)(33.4 m)(24.4 m)(43.2 m)(51.5 m)

Depreciation and Amortization

593 k866 k2 m2.1 m1.7 m

Inventories

(466 k)(1.7 m)920 k

Accounts Payable

106 k90 k(786 k)(437 k)309 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

5.1 m(11 m)(11.1 m)(11.4 m)(15.6 m)(11.6 m)

Depreciation and Amortization

149 k

Inventories

910 k1.3 m1.4 m1.9 m290 k

Accounts Payable

1.2 m2.2 m2.8 m2.9 m1.6 m1.7 m3.6 m2.9 m1.4 m1.7 m786 k
USDY, 2018

EV/EBIT

-15.7 x

EV/CFO

-17.6 x

Financial Leverage

-1.4 x
Show all financial metrics

AcelRx Pharmaceuticals Operating Metrics

FY, 2016

Patents (US)

20

Patents (foreign)

24

Phase III Trials Products

2
Show all operating metrics
Report incorrect company information

AcelRx Pharmaceuticals News and Updates

Report incorrect company information